Jul 2022 – Present · 3 yrs 8 mos · Pune, Maharashtra, India · On-site

• Part of WW Oncology Commercialization Analytics, Managing & Working On Oncology portfolio for a US-based client, overseeing three Oncology products with an annual revenue of $15 Billion (as of FY 2023).
• On Tumor Level:
• My responsibilities includes Supporting Clients with:
• 1. Led Forecasting Cycles (Long-Term Financial Planning) for Thoracic Portfolio (Meta NSCLC, Early NSCLC,Sclc) over my tenure at the
• current project for the Immuno Oncology therapy area for the 3 key brands of pharmaceutical company. The process involves calibration of the models adjusting assumptions such as DoT, Dosage, Epidemiology Analysis, Market Share, OS-PFS Curve adjustment, etc
• 2. Patient-Centric Forecasting: I excel in patient-based forecasting, whether for short-term tactical decisions or long-term strategic planning for Inline & Pipeline Assets.
• 3. Assumption and Forecasting Models: I have a track record of constructing sophisticated models to support forecasting, especially in the early, first-line (1L), and second-line (2L) stages.
• 4. Data-Driven Analysis: I am proficient in conducting comprehensive sales, dosage, and price-based analyses, allowing me to provide asset-level volume forecasts in precise units like milligrams and vials.
• 5. Launch Opportunity Assessment: I conduct thorough reviews, considering factors such as tumor whitespace and epidemiology analysis, to identify launch opportunities for new products.
• 6. Market Share Insights: I offer insights into the historical performance of immuno-oncology (IO) products based on their order of entry into the market.
• 7. Loss of Exclusivity (LOE) Analysis: I am experienced in LOE erosion analysis and analog comparisons to inform strategic decisions & help in Expanding the Portfolio in future.
• 8. Data Proficiency: I am well-versed in handling various datasets, including DRG (Epi), Kantar (Epi), and IQVIA (MIDAS), allowing for robust and evidence-based forecasting and analysis.